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ACTH = adrenocorticotrophic hormone; ARDS = acute respiratory distress syndrome; CO = cardiac output; CT = computed tomography; 
CVP = central venous pressure; CVVHF = continuous venovenous haemofiltration; eNOS = endothelial nitric oxide synthase; ICU = intensive care
unit; LPS = lipopolysaccharide; NO = nitric oxide; PAWP = pulmonary artery wedge pressure; PEEP = positive end-expiratory pressure;
TNF = tumour necrosis factor.
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The opening session
This year’s conference opened with a session influenced
by millennial spirit, reflecting on the ‘coming of age’ of
Intensive Care Medicine, taking stock of the speciality and
in particular, how it can and perhaps should, be evaluated,
as well as speculating about the future.
As in previous years, a round table conference had taken
place over the two days preceding the symposium. This
focused on ‘Evaluating Critical Care: Using health ser-
vices research to improve quality.’ This sobering macro-
scopic view of the cost benefit ratio of intensive care,
especially when compared with much cheaper and more
efficacious interventions, forced all present to reflect on
our work and justify it. The report was timely, when set
against the background of escalating demands for clinical
governance and external audit, both in the UK and Interna-
tionally. This led appropriately, to a presentation and exam-
ination of End of Life management in the intensive care
unit (ICU), which focused on the financial costs. The clear
take home message from the speaker, Derek Angus (Pitts-
burgh, USA), was that this sometimes neglected area
requires a much higher priority, which in turn is likely to
increase costs further.
Immunology and molecular biology were given their dues
with presentations describing the current theories of pro-
vs anti-inflammatory cytokines, and a valuable update on a
groundbreaking area of innate immunity. The cytokine
picture, already complicated to the non-expert, was
plunged further into confusion by new evidence suggesting
that the earlier classification of cytokines into pro- and anti-
inflammatory is at best misleading, and at worst entirely
useless. In direct opposition, the discovery of an intermedi-
ate branch of the immune system, which bridges the gap
between the innate and adaptive systems was refreshingly
simple, offering significant promise for future interventions.
In essence, it appears that even fruit flies make specific
IgM to a few common antigens, and humans seem to do
the same. These constitutive forms of specific immunologi-
cal molecules appear to have important roles in the activa-
tion and modulation of the inflammatory process.
Also noteworthy, was the presentation entitled, ‘Attribut-
able mortality of hypoxaemia’ by Duncan Young (Oxford,
UK). He presented a series of retrospective analyses
which supported the hypothesis that arterial oxygenation
has no correlation with mortality in adult ICU patients. He
argued that this may explain the negative results of recent
studies such as those into the effects of inhaled nitric
oxide and that further studies into interventions that
improve arterial oxygenation are therefore, equally unlikely
to reveal any outcome benefits [1].
Heart–lung interactions
This short session of 3 presentations examined the clinical
applications of the cardiovascular physiology of mechani-
cally ventilated patients. Experimental work was presented
confirming that simple analysis of arterial systolic pressure
variation with respiratory phase accurately predicts biven-
tricular preload. This technique dramatically outperforms
the conventional markers of preload, central venous pres-
sure (CVP) and pulmonary artery wedge pressure
(PAWP) [2].Critical Care    Vol 4 No 3 Ball and Venn
Hepatology
Julia Wendon (London, UK), gave three excellent presen-
tations covering acute liver failure, the hepatorenal syn-
drome [3] and liver trauma. The era of extracorporeal liver
support appears to be tantalisingly close, although current
best practice utilising high flow bicarbonate continuous
venovenous haemofiltration (CVVHF) appears to offer
considerable benefit and is not that far short of this thera-
peutic goal. Hepatectomy as a bridge to transplantation is
increasingly being employed with the anhepatic state sur-
prisingly well tolerated for short periods, often leading to
the stabilisation and improvement of acute liver failure
patients. The early results of vasopressin analogue trials in
the hepatorenal syndrome were presented. These show
encouraging results, albeit with a high incidence of severe
side effects. As regards liver trauma, this can often be
best managed conservatively. The value of repeated com-
puted tomography (CT) imaging and interventional angiog-
raphy was also demonstrated.
Hyperosmotic–hyperoncotic intravenous fluids
A short series of presentations on these comparatively new
fluids demonstrated the theoretical benefits that they offer
and the results of several recent positive trials [4]. There
appears to be a clear role emerging for these fluids both in
the resuscitation of trauma patients and perioperatively.
Their role in other ICU patients awaits further evaluation.
Pressure–volume curves, open lung ventilation
and recruitment
A great number of sessions were devoted to these issues,
which remain controversial. Direct visualisation, using a
variety of radiological techniques, of the pressure volume
changes seen in differing patterns of lung injury seem to
confirm the suspicion that the pressure volume curve is a
poor determinant of optimal ventilatory parameters, espe-
cially the level of positive end-expiratory pressure (PEEP).
The debate on how to best optimise PEEP continues,
although both speakers and the majority of delegates
appear to advocate relatively high values. Several speak-
ers confirmed the value of lung recruitment, although the
method and frequency of such manoeuvres remains con-
tentious. The consensus view appears to favour more fre-
quent, less aggressive manoeuvres than previously
recommended. The impact of the acute respiratory dis-
tress syndrome (ARDS) Network trial [5] awaits full con-
sideration as few of the speakers had had sufficient
opportunity to review it. However the universal adoption of
low tidal volumes in ARDS patients seems likely.
Myocardial dysfunction in sepsis
We normally associate the septic patient with a high
cardiac output (CO), but it is also recognised that these
patients may present with a normal or low CO due to
myocardial dysfunction. This session was devoted to the
mechanisms and clinical implications of this phenomenon.
Keith Walley (Vancouver, Canada) gave an enthusiastic
insight into the role of the leukocyte in contributing to this
combination of reduced systolic contractility and diastolic
stiffness. In his pig model of septic shock, capillaries in the
heart were plugged with leukocytes, retained after an
inflammatory response, and caused actual myocardial
damage. Further experiments using an isolated heart
preparation showed that the use of a leukocyte filter
blocked this reduction in contractility. He concluded that a
variety of mechanisms probably existed to explain why the
retained leukocytes ultimately caused this myocardial
depression including reactive oxygen intermediates, nitric
oxide (NO) and tumour necrosis factor (TNF)a.
Jean-Luc Balligand (Brussels, Belgium) gave an overview
of the complicated picture for NO modulating myocardial
contractility in sepsis. Perhaps the most interesting
message from this speaker was his description of the
recently found b3-adrenoceptor pathway [mediated via
endothelial nitric oxide synthase (eNOS)] which opposes
the classical pathway of positive inotropy mediated by b1 &
b2-adrenoceptors. The expression of this b3-adrenoceptor
is increased when lipopolysaccharide (LPS) is injected into
mice and this may partly explain the hyporesponsiveness of
the heart to inotropes in sepsis. The search is now on for a
b3-adrenoceptor blocker to treat the failing heart in sepsis.
Alexandre Mebazaa (Paris, France) summarised the other
factors thought to affect myocyte function in sepsis. The
cyclooxygenase-2 enzyme is found in abundance after endo-
toxin is injected into rabbits and it is therefore likely that
prostaglandins are important mediators. The role of endothe-
lin is more controversial since although it is found to be ele-
vated in the plasma of septic rats and patients, it is well
known that its concentration in the plasma does not reflect
its paracrine role in the heart. However, it does appear to
induce a time-dependant reduction in cardiac function.
Andrew Rhodes (London, UK) gave an excellent account
of the dobutamine stress test, which provides information
about the intrinsic metabolic function of cells. Mortality
was virtually universal in those patients who were unable
to show an increase in oxygen consumption and delivery
following a short dobutamine infusion.
Finally Lambert Thijs (Amsterdam, The Netherlands) sum-
marised the clinical implications of our knowledge of the
mechanisms involved in sepsis. A variety of historical
experimental approaches were alluded to. The hope is that
haemofiltration may be helpful in the future for removing
these inflammatory mediators of sepsis and reducing
myocardial dysfunction.
Steroids in septic shock and ARDS
This was an excellent session following the history of this
subject and demonstrating how a reduction in dose andhttp://ccforum.com/content/4/3/169
prolonging the duration of steroid administration has
changed a potentially harmful therapy into an exciting
approach to septic shock and ARDS for the 21st century.
Charles Sprung (Jerusalem, Israel) explained his early
involvement in the treatment of septic shock with large
doses of steroids given late in the course of sepsis. Several
studies were unable to show any differences in outcome in
sepsis and ARDS, and a meta-analysis nearly halted the
enthusiasm for the use of steroids, since there was a sug-
gestion that they increased mortality in patients with sepsis.
However, Umberto Meduri (Memphis, USA) presented his
data following prolonged (day 9–28) methylprednisolone
therapy for the management of unresolving ARDS . Infec-
tion surveillance was detailed, and although the study only
involved small numbers, those receiving methylpred-
nisolone showed improvements in lung injury scores,
reduced ventilator days a reduction in pro-inflammatory
cytokines and an increase in anti-inflammatory cytokines.
Piere Bollaert (Nancy, France) discussed the ‘relative’
adrenocortical deficiency seen in 6–20% patients with
sepsis/septic shock. High basal cortisol levels (>34mg/dl)
and low stimulated cortisols to the short adrenocorti-
cotrophic hormone (ACTH) test (<9mg/dl) are high pre-
dictors of death in septic patients. However, neither the
low (1mg) or conventional (250mg) short ACTH tests are
sensitive enough in predicting who will benefit from
steroid therapy in sepsis, and the benefits of steroids may
not be related to this ‘relative’ deficiency. At this point the
audience was surveyed to find that many intensivists were
already using physiological doses of steroids in septic
shock, but that only 50% were performing ACTH stimula-
tion tests in this group.
Herwig Gerlach (Berlin, Germany) described his
crossover study exploring the use of physiological doses
of steroids, given for 3 days, in septic shock. A reduction
in noradrenaline doses was seen in the steroid treated
group reflecting the reversal in vasodilatation. Investiga-
tions to determine the mechanisms behind this effect
revealed reduced nitrite/nitrate production (a surrogate
marker of NO production), reductions in cytokines and
leukocyte adhesion in the steroid group, but interestingly
no evidence of immunosuppression. Unfortunately numbers
were too small to show any outcome benefits.
Finally Djillali Annane (Garches, France) presented his
exciting preliminary data on the results of the PhaseIII
multi-centre, randomised, double-blind trial of low dose
hydrocortisone (50mg, 6 hourly) and fludrocortisone
(50mg/day) in septic shock. A second safety analysis, fol-
lowing the recruitment of 220 patients, showed an impres-
sive 28 day reduction in mortality in the steroid treated
group (placebo 63%, steroid 50%, P=0.029). However
because the primary efficacy variable (mortality in non-
responders to the ACTH stimulation test) did not reach sig-
nificance (P=0.051), the study was completed to enrol all
300 patients. Full results will be available later in the year.
Summary
Once again this International Symposium lived up to its
reputation for providing a diverse mixture of ‘state of the
art’ lectures, seminars and tutorials. Both the clinician and
scientist involved in the critically ill would have found an
abundance of ‘hot-off-the-press’ material to digest prior to
the 21st symposium.
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